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Summary Cancer sera have higher levels of serum protein-bound fucose than sera from healthy individuals.
In an attempt to identify the cause of this increase, fucoproteins were extracted from the sera of cancer
patients and healthy individuals using a fucose-specific lectin (lotus tetragonolobus) coupled to Sepharose, and
were analysed by polyacrylamide gel electrophoresis and silver staining. Of the several consistent changes
observed for the cancer sera, the most striking was a large increase in a component of 40-45 Kdaltons. The
expression of this component in the cancer sera was related to the elevation in serum fucose levels. Two
dimensional (2D) electrophoretic analysis of lectin extracts showed that this component had a similar
isoelectric point to the fi chains of haptoglobin. Its identity as haptoglobin was confirmed using Western
blotting and an anti-haptoglobin antibody. Fucosylated haptoglobins (FHp) were also isolated from some
rheumatoid arthritis sera, but there was no correlation between serum fucose levels and the FHp expression.
The FHp in cancer sera was of higher molecular weight than that found in rheumatoid sera. Serial specimens
from two ovarian cancer patients undergoing chemotherapy had elevated FHp associated with increased
amounts of tumour. To the best of our knowledge this is the first time a molecule of this type has been
reported in cancer sera and because of its uniqueness it deserves further investigation as a potential cancer
marker.
Serum protein-bound focose is frequently elevated in cancer
patients (Turner et al., 1985). This finding cannot be
explained by the production of new glycoproteins, as very
few new proteins are seen on one (ID) or two dimensional
(2D) electrophoresis of cancer sera as compared to the
patterns of healthy sera (Thompson & Turner, unpublished
observations). Other possible explanations include the
increased production of pre-existing serum glycoproteins
and/or alterations in the sugar moieties of these molecules.
The acute phase proteins have been shown to be elevated in
cancer (Turner et al., 1985), but at their known normal levels
of glycosylation (Clamp, 1975) it is unlikely that they can
contribute much to the observed changes in fucose levels.
Whether the fucosylation of serum proteins is altered in
cancer is unclear, the objective of this study was to examine
this possibility. The fucoprotein composition of sera from
healthy individuals, cancer patients and arthritics has been
investigated by using a fucose-specific lectin (lotus) in
combination with electrophoresis. Some of the results have
already been presented as a preliminary report (Thompson &
Turner, 1987).
Materials and methods
A single blood specimen was obtained from 22 cancer
patients (12 men and 10 women; aged 17-67 years), 19
healthy volunteers (6 men and 13 women; aged 18-64 years)
and 11 patients with rheumatoid arthritis (3 men and 8
women; aged 34-75 years) by venepuncture; separated by
low speed centrifugation for 10min, and the sera were stored
at -20°C until required for analysis. The cancer group
consisted of carcinomas unless stated otherwise. These were
from the following sites: ovary 3; breast 3; teratoma 3; colon
2; lung 2; lymphoma 2; hepatoma 1; prostate 1; stomach 1;
sarcoma 1; bile duct 1; kidney 1; melanoma 1. The cancer
patients were either hospitalised or attending an outpatient
clinic, were receiving a variety of chemotherapeutic treat-
ments, and in the majority of cases the tumour had spread
extensively and the disease was progressive; sera from this
group will be subsequently designated as 'cancer'. The latter
sera were chosen for the level of protein-bound fucose in
their sera rather than for any particular clinical attribute.
Two of the women with ovarian cancer provided serial speci-
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mens throughout their chemotherapy (cyclophosphamide),
and during this time of collection they showed evidence
of tumour remission followed by recurrence of tumour
growth. The terms remission and recurrence have been
previously defined (Turner et al., 1982). Healthy volunteers
were all individuals who attended a blood transfusion
session, they had no known disease present and none of
them were on medication or oral contraceptives; this group
will be subsequently designated as 'healthy'. All the rheuma-
toid patients were attending an outpatient clinic, 5 had
active disease and 8 were receiving medication; this group
will be subsequently designated as 'rheumatoid'.
Lotus-lectin (lotus tetragonolobus; Sigma Chemical Co.
Ltd., Poole, Dorset, UK) was coupled to CNBr activated
Sepharose 4B beads (Pharmacia Ltd., Milton Keynes, UK)
at a final concentration of 2mg lectinml-l packed beads
using the method described in the Pharmacia handbook
Affinity Chromatography. Immediately prior to use, the
lectin-beads were washed three times with 2.5ml 0.05moll-1
Tris-HCl buffer, pH7.4 containing 25mmoll- KCI,
5mmolI1- CaCl25 5mmol 1- I MgCl2 and 0.5% (v/v)
Nonidet P40. One volume of packed lectin-beads (50-100 ul)
was mixed with one volume of serum (50-100 l) in a 3ml
plastic tube (LP3-Luckham Ltd., Burgess Hill, Sussex, UK)
for 30-40min at 25°C or for 1-2h at 4°C. The reaction tube
was gently agitated by hand every 10min to ensure mixing of
beads and serum. The beads were then washed 6 times
(natural settling or gentle centrifugation at 4°C) with the
above Tris-buffer to remove unbound serum components.
In pilot studies, bound glycoproteins were removed from
the lectin-beads by either incubation for 30min with 50-
100 d of the Tris washing buffer containing 0.5moll-1
fucose, or by solubilising in 50-100 l of 125mmoll-1 Tris
HCI buffer pH6.8, containing 0.35moll-1 sodium dodecyl
sulphate (SDS), 2.7mol -1 glycerol, 1 mmolI- EDTA,
2.9mmolI1 bromophenol blue. Both these elution methods
gave similar protein staining patterns after electrophoresis,
but SDS appeared to elute all the components in greater
amounts, therefore, this method was used to prepare the
material for ID-electrophoretic analyses. In 2D-analyses,
material was always eluted with fucose because SDS
interferes with the electrofocusing step. Two lectins with
fucose affinity (lotus and gorse) were originally screened for
their reactivity with serum glycoproteins, but lotus lectin was
eventually chosen for this study because the extracted
glycoproteins gave a clearer and more reproducible pattern
on electrophoresis.
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Serum glycoproteins and fucoprotein extracts were
analysed by ID and 2D polyacrylamide gel electrophoresis as
previously described (Thompson & Maddy, 1982). Prior to
1 D-electrophoresis, SDS-eluted material, or fucose-eluted
material mixed with an equal volume of the SDS buffer, was
reduced by the addition of /3-mercaptoethanol to a final
concentration of 0.72 moll-1 and boiling for 5min. All
eluates (10-30jil/SDS; 20-50pl/focuse) were then separated
in 8% (w/v) polyacrylamide gels. Electrophoresis was carried
out for 3.5h at 40mA/slab using the discontinuous Laemmli
buffer system. For 2D-electrophoresis, 0.5 MI of unfractionated
serum or 20,ul of the fucose eluate was separated by
isoelectro-focusing (500V for 20h) in pH3.5-10 gradients in
4% (w/v) polyacrylamide tube gels. After equilibration in
sample buffer containing 5% (w/v) SDS, the tube gels were
electrophoresed in a 8% (w/v) polyacrylamide second
dimension. Separated proteins were stained with silver using
a procedure similar to that described by Morrissey (1981).
The latter method was modified by prefixing the gels in a
solution containing 4.4moll-1 ethanol and 1.7moll-1 acetic
acid for 2h at 25°C; leaving out the glutaraldehyde step and
increasing the dithiothreitol and silver nitrate treatment steps
to 2h. These modifications reduced the background staining
and gave more reproducible results. Molecular weight
markers were RNA polymerase (165, 155 and 39 Kdaltons
(Kd), phosphorylase B (94 Kd) and serum albumin (68 Kd).
Western blotting and detection of antigen-antibody
alkaline phosphatase-conjugated anti-antibody complexes
were carried out by the method of Blake et al. (1984).
Rabbit anti-human haptoglobin (Dakopatts) was used at a
dilution of 1/1000 as the first layer and alkaline phosphatase-
sheep anti-rabbit (Serotec) was used at the same dilution as
the second layer.
Serum fucose and haptoglobin levels were measured using
previously described methods (Turner et al., 1985).
Results
Figure 1 compares the 1D-electrophoresis patterns of
fucosylated serum glycoproteins isolated from three cancer
patients with those isolated from three age and sex matched
healthy volunteers. At the bottom of this figure and Figures
2, 4, 5 and 7 are given the levels of serum protein-bound
fucose. The particular 'cancer' sera shown in Figure 1 were
investigated because of their high levels of serum fucose.
Several reproducible differences can be seen between the
'healthy' and 'cancer' samples, but the largest difference is
the increased expression of a 40-45Kd glycoprotein in the
(cancer' extracts.
Figure 2 shows the ID-patterns of lectin extracts from 12
'cancer' sera. These were analysed in two runs of 6
specimens per run. Two of the specimens shown in Figure 2a
(specimens with fucose levels '4.6' and '4.8') are the same as
the ones shown in Figure 1. These are included to illustrate
the reproducibility of the analytical method. It can be seen
from the data in Figure 2 that the elevation in the 40/45 Kd
fucoprotein is consistently detected in 'cancer' sera that have
an elevated fucose level. For two of the specimens in Figure
2a, the 40/45 Kd band was hardly detected; however, in one
case the fucose level was below the upper limit of the normal
range (1.8mgg-1 serum protein: Turner et al., 1985), and in
the other, the level was just above the normal range.
A 2D-separation of a lectin extract from a typical 'cancer'
sera is shown in Figure 3. The position of the 40/45 Kd
molecules is indicated by a large arrow-head where there
appears to be two sets of strongly staining spots that focus
between pH 4.8 and 5.8. These components were tentatively
identified as the # subunits of haptoglobin because of their
position on the 2D gel. Haptoglobin has 2 ,B subunits
(Mr 40Kd) and 2 a subunits (Mr 10Kd) (Nilsson et al.,
1981) and the ,B subunits focus over a similar pH range
(Tracy et al., 1982) to that observed for the extracted
40/45 Kd molecules.
The identity of the 40-45 Kd molecule as P subunits of
haptoglobin was confirmed in two ways. Firstly, an eluate
from a lectin extract of a 'cancer' sera with high fucose levels
was radioiodinated as described previously (Stern et al.,
1984), mixed with cold proteins from a 'healthy' serum and
separated by 2D-electrophoresis. The radioactive 40-45Kd
molecules from this mixture ran in the same position as the
silver stained haptoglobin molecules (# subunits) of the
unextracted serum (data not shown).
Secondly, a Western blot of a ID-separation of 4 'healthy'
and 7 'cancer' extracts was subsequently treated with an
anti-haptoglobin antibody (Figure 4). Below the blot is
presented the 40/45Kd portion from another 1D-separation
in which the same samples were silver stained. The particular
'cancer' specimens analysed were chosen to cover a wide
range of serum fucose concentrations, and the data are
presented for ascending fucose levels. It can be seen that the
antibody detects a strong diffuse band at 40-45Kd in the
'cancer' sera with highly elevated fucose levels ('3.3' and
'3.2'). Even 'cancer' sera with less elevated fucose levels
('1.9', '2.0', and '2.4') show a shift in the position of the
haptoglobin band to higher molecular weights and/or an
increase in intensity compared with the 'healthy' sera.
Figure 5 compares the anti-haptoglobin blots of fuco-
proteins isolated from 6 'healthy' and 5 'rheumatoid' sera; a
silver-stained inset is also shown below. A further 6
'rheumatoid' sera extracts were analysed by silver staining
(data not shown). Elevated levels of fucosylated haptoglobins
(FHp) were detected in 6 out of 11 of the rheumatoid
specimens. The molecular weights of these species were lower
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Figure 1 Electrophoretic separation of fucoprotein extracts of
sera (25,l of extract loaded) from 3 healthy volunteers and 3
cancer patients. Changes in the composition of extracts of the
'cancer' group are indicated by solid triangles (increases) and
open triangles (decreases). In Figures 1, 2, 4, 5 and 7; serum
protein-bound fucose levels are given below the separations in
mg fucose g-I protein; the positions of the mol. wt markers are
indicated at the side of the patterns. In Figures 1, 4, 5; N or
Normal='healthy'. The largest difference between the healthy
and the cancer groups (40-45Kd) is shown by a large arrow on
the right hand side of the gel; this band is similarly indicated on
Figure 2.
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Figure 2 Electrophoretic separations of fucoprotein extracts from 12 'cancer' patients. Aliquots of 30 ,l (a) and 15pl (b) were
separated in two different experiments with two different batches of lectin. Background contaminants between 50-70Kd are
stained more heavily in (b) because the stain was developed longer due to lower sample loading.
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Figure 3 2D-electrophoretic pattern of a lectin extract from a
'cancer' serum. The position of the 40-45Kd molecules is
indicated by a large arrowhead. First dimension (1)=electro-
focusing; Second dimension (2)=electrophoresis.
than those observed for the 'cancer' sera (cf. Figures 4 and
5). This was further confirmed by the data in Figure 6 which
shows part of a ID-separation of 4 pairs of 'cancer' and
'rheumatoid' extracts that were separated in adjacent lanes.
The difference in the mobility of FHp in the pairs of
specimens is clearly evident. There was no relationship
between the serum fucose level and FHp expression in the
'rheumatoid' extracts, but there was an association between
elevated FHp and those individuals that had active disease at
the time of taking the blood specimen. FHp was not elevated
in the 'healthy' extracts analysed in Figure 5.
Figure 7 shows the content of FHp in serial serum
specimens from two women with ovarian cancer who were
undergoing chemotherapy. The specimens were taken on 5
or 6 occasions; 1 or 2 at the start of chemotherapy when
tumour burden was high; 2 during clinical remission when
tumour burden was very low; and finally 2 when a
recurrence of tumour growth had occurred. Only the FHp
regions of the lD-patterns are shown with serum fucose and
haptoglobin levels also listed. Results are given for two
different sample loadings. Values of fucose or haptoglobin
outside the normal reference range are underlined. For both
patients, the expression of FHp and the elevation of fucose
was correlated with the presence of increased amounts of
tumour. Levels of haptoglobin also correlated with the
presence of more tumour, but only one measurement for
each patient was above the normal reference range
(>3.3gI-1: Turner et al., 1985).
Other experiments were carried out to determine the
amount of fucosylated glycoproteins removed from sera by
extraction with lotus lectin. Ten sera (5 'healthy' and 5
'cancer') were extracted with either lotus-coupled Sepharose
beads or control inactive beads, as described in the
experimental section. The 'cancer' sera that were used all had
elevated fucose levels. After treatment, fucose levels were
measured in the sera (extracted and controls). Lotus
treatment removed on average, 0.17mg fucoseg-1 protein
(SD=0.04) from the 'healthy' sera and 0.19mg fucoseg-1
protein (SD=0.03) from the 'cancer' sera; this represented
13.8% and 6.4% of the total fucose in the respective sera
prior to extraction.
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Figure 4 An anti-haptoglobin Western blot comparing 4 'healthy' and 7 'cancer' fucoprotein extracts (30pl of extract loaded). An
inset is shown below the blot which is the portion of a silver stained gel corresponding to the haptoglobin region of the same
samples.
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Figure 5 An anti-haptoglobin Western blot of 6 'healthy' and 5 'rheumatoid' fucoprotein extracts (20 ud of extract loaded),
compared to the silver stained haptoglobin region of the same samples (inset).
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Figure 6 Electrophoretic separations of fucoprotein extracts
from 4 cancer patients (C) and 4 patients with rheumatoid
arthritis (R). Extracts from the different groups were separated
in adjacent lanes to emphasize the difference in molecular weight
of the haptoglobin in the two preparations. Only part of the
silver stained pattern is shown, and the approximate positions of
haptoglobin on the pattern are indicated by arrow-heads on the
right-hand side.
The residual serum after lotus extraction was examined by
2D-electrophoresis. There was no detectable change in the
haptoglobin pattern compared to that obtained with
unextracted serum (data not shown). This showed that the
amount of extracted haptoglobin was very small compared
to the total amount of haptoglobin present.
Discussion
Using the fucose-specific lectin, lotus tetragonolobus, we have
shown that a type of haptoglobin can be extracted from
cancer sera that is present in healthy sera in very much lower
levels. Other differences in the fucoprotein content between
these sera were observed but these were less prominent. To
what extent these abnormally fucosylated molecules can
contribute to the elevated fucose levels is still uncertain.
Although the expression of FHp appeared to broadly reflect
increases in total fucose, the amounts extracted by the lotus
were very small. It is possible that the latter represent only a
small fraction of the total number of molecules which have
modified fucosylation.
Without further investigation it is impossible to under-
stand the precise nature of the haptoglobin abnormality
that is occurring in cancer, but our current knowledge of
lotus specificity and haptoglobin structure provides a likely
explanation for the observed change. Lotus specificity is
directed towards fucose that is linked in either a a-(1-2)
position to a subterminal galactose or in a a-(1-6) position
to a N,N'-diacetylchitobiose core (Petryniak & Goldstein,
1986). Haptoglobin has four carbohydrate sidechains per
fl-subunit and fucose is present both in a core a-(1-6) position.
and in a a-(1-3) position on an external N-acetylglucosamine
residue (Tsuji et al., 1981). It might be predicted, therefore,
that because of the a-(1-6) linkage, lotus would extract
haptoglobin in similar amounts from healthy and cancer
sera. This was not the case. Debray et al. (1981) have shown
that substitution of an a-(1-6) linked fucose-N-acetylglucos-
amine disaccharide with further mono- or oligo-saccharides
1 la A a a 7 a a I n I
decreases its affinity for lotus, unless a further fucose
substitution is present at the ae-(1-3) location on the added
oligosaccharide. This suggests that in healthy sera different
fucose linkages on haptoglobin are on different side-chains,
whereas in cancer both types of linkage are present on the
same side-chain. This explanation is also supported by our
preliminary findings using lentil lectin. High affinity binding
to lentil has a stringent requirement for the presence of fucose
in the chitobiose core cx-(1-6) linkage (Kornfeld et al., 1981).
Our experiments show that this lectin can isolate haptoglobin
from both 'cancer' and 'healthy' sera (data not shown).
Lotus lectin extracted FHp from the sera of patients with
rheumatoid arthritis, but this was different to the cancer
material in three respects. Firstly, the cancer haptoglobin
contained molecules of higher molecular weight; secondly,
the presence of rheumatoid haptoglobin was not related to
the serum fucose level; and finally the rheumatoid
haptoglobin frequently appeared as sharp bands whereas
that from cancer patients was always diffuse (cf. Figures 1
and 2 with Figure 5). Recently, we have been unable to
detect FHp in sera from broncho-pneumonia patients, even
though they had massively elevated haptoglobin levels
(unpublished observations). This also suggests that the
changes we have detected in cancer are specific.
FHp may be useful as a tumour marker in ovarian cancer,
because its expression appears to be associated with the
presence of increased amounts of tumour growth. Very
recent studies have confirmed this finding in a further group
of thirteen ovarian cancer patients (unpublished obser-
vations). Haptoglobin is normally synthesized by the liver
(Koj, 1974), but it may also be synthesized by some tumour
cells (Yoshimara, 1978). Both of the cancer patients provided
the serial specimens for the current study were noted to have
possible liver involvement at a prior laparotomy. Whether
this involvement disappeared during the reported tumour
remission, and the observed reduction in FHp, is unknown.
Although more extensive studies are required to establish the
usefulness of FHp as a cancer marker, it may turn out to be
better in this respect than either fucose or haptoglobin. We
have already shown that FHp has better specificity than
fucose, and unlike total haptoglobin, it is very low in
specimens from healthy individuals, immediately rising above
the reference level when increased tumour is present (see
Figure 7). As we know that FHp can be detected using an
anti-haptoglobin antibody we plan to develop an automated
nephlometric procedure based on this reagent. This will
allow us to rapidly assay many serum extracts, in a
quantitative and objective manner, and so assess the value of
FHp in monitoring cancer.
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Figure 7 Fucosylated haptoglobin levels in serum samples taken throughout the course of treatment of 2 patients with ovarian
cancer. (a) and (b) are 10p1 and 25 1 loadings respectively. Samples 1, 2 and 7 were taken when tumour was present initially,
samples 3, 4, 8 and 9 during remission and samples 5, 6, 10 and 11 on recurrence of tumour. Fucose and total haptoglobin levels
are shown on this figure; values outside the normal reference range are underlined.
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